The thesis

PRVA partners with medical groups to optimize physician practices. The company's 25.8% revenue growth and 97.0% net margin are notable. With a conviction score of 35/100, the setup is interesting. The analyst consensus rating is BUY, despite a high P/E of 135.7x,

Why now

The current macro context, with the US-China squeeze and Middle East war, creates uncertainty. PRVA's high valuation multiple, such as a P/E of 135.7x, makes it vulnerable to market shifts,

What to watch

Revenue growth and net margin performance over the next quarter will be key indicators. The company's ability to maintain its high valuation multiple will depend on meeting or exceeding analyst expectations,

Key risks

Valuation risk is a major concern, given the high P/E ratio. Execution risk is also a factor, as the company must maintain its high revenue growth. Macro risk, including geopolitical tensions, could impact the healthcare sector,